Control of Constipation in Patients Receiving CHOP or CHOP-Like Chemotherapy Regimens for Non-Hodgkin’s Lymphoma
-
- Hayashi Hiroko
- Department of Pharmacy, Gifu University Hospital
-
- Suzuki Akio
- Department of Pharmacy, Gifu University Hospital
-
- Ohata Koichi
- Department of Pharmacy, Gifu University Hospital
-
- Ishihara Masashi
- Department of Pharmacy, Gifu University Hospital
-
- Kubota Yushi
- Department of Pharmacy, Gifu University Hospital
-
- Kobayashi Ryo
- Department of Pharmacy, Gifu University Hospital
-
- Shibata Yuhei
- First Department of Internal Medicine, Gifu University Graduate School of Medicine
-
- Nakamura Hiroshi
- First Department of Internal Medicine, Gifu University Graduate School of Medicine
-
- Nakamura Nobuhiko
- First Department of Internal Medicine, Gifu University Graduate School of Medicine
-
- Kitagawa Junichi
- First Department of Internal Medicine, Gifu University Graduate School of Medicine
-
- Tsurumi Hisashi
- First Department of Internal Medicine, Gifu University Graduate School of Medicine
-
- Shimizu Masahito
- First Department of Internal Medicine, Gifu University Graduate School of Medicine
-
- Itoh Yoshinori
- Department of Pharmacy, Gifu University Hospital
この論文をさがす
抄録
<p>Management of constipation in patients receiving cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) or CHOP-like chemotherapy regimens is important for prevention of paralytic ileus. We reported earlier that the laxative action of magnesium oxide is reversed by the concomitant use of antacids in cancer patients receiving opioid analgesics. Here, we assessed the prevalence of prophylactic laxative medication for the control of constipation in patients receiving CHOP or CHOP-like regimens for non-Hodgkin’s lymphoma. Data obtained from 211 eligible patients were retrospectively analyzed. Almost all patients (99%) received anti-ulcer agents such as proton pump inhibitors and H2 receptor antagonists for the prophylaxis of gastric disorders associated with prednisolone. Prophylactic laxatives were prescribed in 86 patients (40.8%), in which magnesium oxide was used most predominantly (88.4%). However, magnesium oxide at doses of ≦2000 mg/d was not effective for prevention of constipation, although the compound totally inhibited the incidence of constipation at doses higher than 2000 mg/d. Therefore, it is important to avoid negative drug interaction between magnesium oxide and antacids in patients receiving CHOP chemotherapy.</p>
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 40 (5), 698-702, 2017
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204633651328
-
- NII論文ID
- 130005631952
-
- NII書誌ID
- AA10885497
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 028137993
-
- PubMed
- 28458356
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可